Royalty Pharma to Pay Sunesis $25M for Future Royalties from AML Drug Sales – Genetic Engineering News

The anticancer quinolone derivative (AQD) is being evaluated in a pivotal Phase III study, termed Valor, which is currently enrolling 450 patients with first relapsed or refractory AML. The trial employs an adaptive design that will allow the …